Cloverleaf Bio has raised $33.0M in seed funding to advance its work on a new class of RNA therapeutics aimed at transforming cancer treatment. The round marks a significant early bet on the company鈥檚 platform, which seeks to harness RNA鈥檚 potential in ways that could shift how oncologists approach the disease.
The biotech startup is developing therapies that target cancer at the molecular level, though specifics on the technology remain under wraps. With this capital, Cloverleaf is positioned to push its research forward, though the company has not disclosed which investors led or participated in the round. The funding underscores growing investor appetite for RNA-based approaches beyond vaccines, particularly in oncology, where precision and adaptability are prized.

















